A photo of Thomas D. Ryan.

Thomas D. Ryan, MD, PhD

  • Associate Director, Heart Failure & Cardiomyopathy Program
  • Director, Cardio-Oncology Program
  • Co-Chair, Institutional Review Board
  • Professor, UC Department of Pediatrics
I treat each patient and family as individuals who are experiencing their healthcare journey for the first time. My job is to explain and advocate for the best care.
Thomas D. Ryan, MD, PhD



I am a pediatric cardiologist with special interests in cardiomyopathy, heart failure and heart transplantation. I also treat patients who have developed cardiovascular dysfunction as a result of cancer or cancer therapies, which is a specialty area called cardio-oncology.

I was drawn to my career as far back as high school, when I was intrigued by the workings of the heart in an anatomy and physiology class. In graduate school, I studied the mechanisms of heart failure, and during clinical rotations in medical school, I found I really enjoyed interactions with pediatric patients. I also valued the relationships I formed with parents and caregivers.

In my practice, I treat each patient and family as individuals who are experiencing their healthcare journey for the first time. Aspects of care that may be routine to healthcare providers can be frightening, frustrating or confusing to patients and families. My job is to explain and advocate for the best care. There is often not a right approach for all patients, but there is a right approach for an individual patient.

I have a particular interest in cardio-oncology, and I am the founding co-director of the Cardio-Oncology Program at Cincinnati Children’s, one of the first such pediatric programs in the country. I also have an interest in genetic cardiomyopathies as well as acquired cardiomyopathy.

I am proud to be a graduate of the Medical Scientist Training Program at the University of Alabama at Birmingham, where I earned both an MD and a PhD. I am director of clinical operations for Cincinnati Children’s Cardiomyopathy and Advanced Heart Failure Clinic, and a founding member of the Leadership Council for the Cardio-Oncology Member Section of the American College of Cardiology.

In addition to patient care, I’m engaged in research. I am studying possible avenues for preventing heart dysfunction from cancer therapies. I’m also investigating improved care for patients after heart transplant and seeking a better understanding of cardiovascular disease in neuromuscular disorders such as Duchenne muscular dystrophy.

BS: Wichita State University, Wichita, KS, 1996. 

PhD: University of Alabama at Birmingham, Birmingham, AL, 2004.

MD: University of Alabama at Birmingham, Birmingham, AL, 2005.

Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2006-2009.

Fellowship: Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2009-2012.

Advanced Fellowship: Pediatric Heart Failure/Transplant, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2012-2013.

Certification: American Board of Pediatrics, 2010; American Board of Pediatrics, Sub-board of Pediatric Cardiology, 2012; International Cardio-Oncology Society Certified Cardio-Oncologist, 2023.


Cardiomyopathy; cardio-oncology; heart transplant; mechanical circulatory support

Services and Specialties

Neuromuscular Disorders, Cardiomyopathy, Heart Failure, Rasopathy, Cardio-Oncology, Heart, Neuromuscular Cardiology


Cardiomyopathy; cardio-oncology; heart transplant

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information



Heart Transplantation in Muscular Dystrophy Patients: Is it a Viable Option?. Wells, D; Rizwan, R; Jefferies, JL; III, BR; Ryan, TD; Lorts, A; Chin, C; Zafar, F; Morales, DL. Circulation: Heart Failure. 2020; 13:e005447.


Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, B; Laskin, BL; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, AS; Nelson, A; et al. Blood. 2020; 135:1049-1057.


Wearable cardioverter-defibrillators in pediatric cardiomyopathy: A cost-utility analysis. Evers, PD; Anderson, JB; Ryan, TD; Czosek, RJ; Knilans, TK; Spar, DS. Heart Rhythm. 2020; 17:287-293.


The landscape of cardiovascular care in pediatric cancer patients and survivors: a survey by the ACC Pediatric Cardio-Oncology Work Group. Ryan, TD; Border, WL; Baker-Smith, C; Barac, A; Bock, MJ; Canobbio, MM; Choueiter, NF; Chowdhury, D; Gambetta, KE; Glickstein, JS; et al. Cardio-Oncology. 2019; 5:16.


Conservative gadolinium administration to patients with Duchenne muscular dystrophy: decreasing exposure, cost, and time, without change in medical management. Lang, SM; Alsaied, T; Moore, RA; Rattan, M; Ryan, TD; Taylor, MD. International Journal of Cardiovascular Imaging. 2019; 35:2213-2219.


New-onset diabetes after pediatric heart transplantation: A review of the Pediatric Heart Transplant Study. Sparks, JD; Cantor, RS; Pruitt, E; Kirklin, JK; Carboni, M; Dreyer, W; Kindel, S; Ryan, TD; Morrow, WR. Pediatric Transplantation. 2019; 23:e13476.


Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week. Hayek, SS; Ganatra, S; Lenneman, C; Scherrer-Crosbie, M; Leja, M; Lenihan, DJ; Yang, E; Ryan, TD; Liu, J; Carver, J; et al. Journal of the American College of Cardiology. 2019; 73:2226-2235.


Contemporary Outcomes of Pediatric Restrictive Cardiomyopathy: A Single-Center Experience. Wittekind, SG; Ryan, TD; Gao, Z; Zafar, F; Czosek, RJ; Chin, CW; Jefferies, JL. Pediatric Cardiology. 2019; 40:694-704.


Treatment exposures stratify need for echocardiographic screening in asymptomatic long-term survivors of hematopoietic stem cell transplantation. Rotz, SJ; Powell, A; Myers, KC; Taylor, MD; Jefferies, JL; Lane, A; El-Bietar, JA; Davies, SM; Dandoy, CE; Ryan, TD. Cardiology in the Young. 2019; 29:338-343.


Cardiopulmonary Aerobic Fitness Assessment During Maximal and Submaximal Exercise Testing in Pediatric Oncology Patients After Chemotherapy. Powell, AW; Nagarajan, R; Mays, WA; Chin, C; Knilans, TK; Knecht, SK; Amos, MA; Gerdes, YM; Ryan, TD. American Journal of Clinical Oncology: cancer clinical trials. 2018; 41:1058-1061.

From the Blog

What You Need To Know About Cardiomyopathy Right Now
Blog Heart ConditionsHeart Conditions

What You Need To Know About Cardiomyopathy Right Now

By Thomas Ryan, MD, PhD9/29/2016

Top Questions About Genetic Testing for Cardiomyopathy
Blog Heart Conditions

Top Questions About Genetic Testing for Cardiomyopathy

By Thomas Ryan, MD, PhD8/27/2015

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Overall Patient Rating